KR20190020946A - A composition for preventing or improving skin wrinkle comprising herb extracts or fermentation products thereof - Google Patents
A composition for preventing or improving skin wrinkle comprising herb extracts or fermentation products thereof Download PDFInfo
- Publication number
- KR20190020946A KR20190020946A KR1020170105907A KR20170105907A KR20190020946A KR 20190020946 A KR20190020946 A KR 20190020946A KR 1020170105907 A KR1020170105907 A KR 1020170105907A KR 20170105907 A KR20170105907 A KR 20170105907A KR 20190020946 A KR20190020946 A KR 20190020946A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- green tea
- extract
- composition
- cinnamon
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 230000037303 wrinkles Effects 0.000 title claims abstract description 48
- 239000000284 extract Substances 0.000 title claims description 119
- 230000004151 fermentation Effects 0.000 title 1
- 238000000855 fermentation Methods 0.000 title 1
- 244000269722 Thea sinensis Species 0.000 claims abstract description 46
- 235000009569 green tea Nutrition 0.000 claims abstract description 39
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 36
- 235000006533 astragalus Nutrition 0.000 claims abstract description 31
- 210000002826 placenta Anatomy 0.000 claims abstract description 29
- 239000002537 cosmetic Substances 0.000 claims abstract description 24
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 21
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 21
- 235000012907 honey Nutrition 0.000 claims abstract description 19
- 235000018865 Angelica gigas Nutrition 0.000 claims abstract description 18
- 240000001810 Angelica gigas Species 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 8
- 241000736199 Paeonia Species 0.000 claims description 28
- 239000000047 product Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 18
- 241000219780 Pueraria Species 0.000 claims description 16
- 235000005687 corn oil Nutrition 0.000 claims description 16
- 239000002285 corn oil Substances 0.000 claims description 16
- 230000006872 improvement Effects 0.000 claims description 15
- 241001608472 Bifidobacterium longum Species 0.000 claims description 12
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 11
- 239000004310 lactic acid Substances 0.000 claims description 9
- 235000014655 lactic acid Nutrition 0.000 claims description 9
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 5
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 4
- 244000105624 Arachis hypogaea Species 0.000 claims description 4
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 4
- 235000018262 Arachis monticola Nutrition 0.000 claims description 4
- 241000186000 Bifidobacterium Species 0.000 claims description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 4
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 4
- 244000199866 Lactobacillus casei Species 0.000 claims description 4
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 4
- 240000007594 Oryza sativa Species 0.000 claims description 4
- 235000007164 Oryza sativa Nutrition 0.000 claims description 4
- 241000001727 Tropicoporus linteus Species 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 235000020232 peanut Nutrition 0.000 claims description 4
- 235000009566 rice Nutrition 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 241001105098 Angelica keiskei Species 0.000 claims 3
- 240000007087 Apium graveolens Species 0.000 claims 3
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims 3
- 235000010591 Appio Nutrition 0.000 claims 3
- 244000000626 Daucus carota Species 0.000 claims 3
- 235000002767 Daucus carota Nutrition 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 39
- 239000004480 active ingredient Substances 0.000 abstract description 32
- 102000029816 Collagenase Human genes 0.000 abstract description 15
- 108060005980 Collagenase Proteins 0.000 abstract description 15
- 108010035532 Collagen Proteins 0.000 abstract description 14
- 102000008186 Collagen Human genes 0.000 abstract description 14
- 229920001436 collagen Polymers 0.000 abstract description 14
- 229960002424 collagenase Drugs 0.000 abstract description 14
- 230000002401 inhibitory effect Effects 0.000 abstract description 14
- 241000759833 Cornus officinalis Species 0.000 abstract description 4
- 241000405911 Rehmannia glutinosa Species 0.000 abstract description 4
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract description 4
- 240000006079 Schisandra chinensis Species 0.000 abstract description 4
- 241000533367 Cnidium officinale Species 0.000 abstract description 3
- 244000046146 Pueraria lobata Species 0.000 abstract description 3
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 3
- 241000612118 Samolus valerandi Species 0.000 abstract description 3
- 231100001083 no cytotoxicity Toxicity 0.000 abstract description 2
- 239000012676 herbal extract Substances 0.000 abstract 3
- 241000045403 Astragalus propinquus Species 0.000 abstract 2
- 241000720991 Illicium Species 0.000 abstract 2
- 230000001851 biosynthetic effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 45
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 24
- 238000004519 manufacturing process Methods 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 241000411851 herbal medicine Species 0.000 description 16
- 239000006071 cream Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 239000004615 ingredient Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- -1 3-butylene glycol Chemical compound 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 235000016709 nutrition Nutrition 0.000 description 11
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000036570 collagen biosynthesis Effects 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000009759 skin aging Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000011785 micronutrient Substances 0.000 description 5
- 235000013369 micronutrients Nutrition 0.000 description 5
- 230000037394 skin elasticity Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- HLXRWTJXGMHOFN-XJSNKYLASA-N Verbenalin Chemical compound O([C@@H]1OC=C([C@H]2C(=O)C[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HLXRWTJXGMHOFN-XJSNKYLASA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010075254 C-Peptide Proteins 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000004177 elastic tissue Anatomy 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000018386 EGF Family of Proteins Human genes 0.000 description 2
- 108010066486 EGF Family of Proteins Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 240000006927 Foeniculum vulgare Species 0.000 description 2
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 240000002045 Guettarda speciosa Species 0.000 description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- YTZSBJLNMIQROD-SFBCHFHNSA-N Morroniside Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)O[C@@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YTZSBJLNMIQROD-SFBCHFHNSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- HLXRWTJXGMHOFN-UHFFFAOYSA-N Verbenalin Natural products C12C(C)CC(=O)C2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O HLXRWTJXGMHOFN-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 240000008866 Ziziphus nummularia Species 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YTZSBJLNMIQROD-UHFFFAOYSA-N (4aS)-1c-beta-D-glucopyranosyloxy-6xi-hydroxy-8t-methyl-(4ar,8ac)-5,6,8,8a-tetrahydro-1H,4aH-pyrano[3,4-c]pyran-4-carboxylic acid methyl ester Natural products C12C(C)OC(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O YTZSBJLNMIQROD-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000207892 Convolvulus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 235000008227 Illicium verum Nutrition 0.000 description 1
- 240000007232 Illicium verum Species 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241001400472 Omiza Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000269908 Platichthys flesus Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 description 1
- 244000086363 Pterocarpus indicus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 230000003366 colagenolytic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 210000004993 mammalian placenta Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000019654 spicy taste Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 229940032362 superoxide dismutase Drugs 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
- A61K8/988—Honey; Royal jelly, Propolis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Abstract
Description
본 발명은 한약재 추출물 또는 이의 발효물을 포함하는 피부 주름 예방 또는 개선을 위한 조성물에 관한 것으로, 보다 구체적으로는 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반 추출물 또는 이들의 추출 발효물 및 꿀을 유효성분으로 포함하는 피부 주름 예방 또는 개선을 위한 화장료 조성물, 약학적 조성물 및 식품 조성물에 관한 것이다. The present invention relates to a composition for prevention or improvement of skin wrinkles comprising a medicinal herb extract or a fermented product thereof, and more particularly to a composition for preventing or improving wrinkles of a skin including a medicinal herb extract or a fermented product thereof. The present invention also relates to a cosmetic composition, a pharmaceutical composition and a food composition for prevention or improvement of skin wrinkles containing an extract of a donkey placenta, fermented extract thereof and honey as an active ingredient.
피부는 노화가 일차적으로 나타나는 기관으로 이를 지연 또는 예방하기 위하여 화장품 영역에서도 많은 연구가 진행되어 왔다. 통상적으로 피부노화는 25세를 전후하여 진행되기 시작하여 40세를 전후한 시기에 본격적으로 피부노화가 진행된다. 피부노화의 대표적 현상으로 피지 분비량이 감소되어 피부가 건조해지고, 세포 재생이 늦어지고, 노화 각질이 많이 쌓여서 피부가 거칠어지는 특징이 있다. 또한, 표피를 지탱해주는 콜라겐의 합성량이 감소되고 엘라스틴(탄력섬유)이 변성되어 주름이 생긴다. 아울러, 피부색이 얼룩지고 기미, 검버섯 등과 색소 침착 증상이 나타나며, 표피가 얇아져서 피부보호 기능이 약화된다. 그 밖의 현상으로는 피부 두께의 감소와 관련된 피부 장벽작용(Barrier Effect)의 저하로 인한 피부 트러블의 증가를 들 수 있다. 피부노화와 관련된 연구는 크게 피부노화의 주요원인이 되는 자외선과 활성산소로부터 피부를 보호하는 소재, 피부주름 개선 소재, 피부탄력 증진 소재, 피부 보습력 강화소재, 기미 생성억제에 관련된 소재로 분류할 수 있다. Skin is the primary organ of aging, and much research has been done in the field of cosmetics to delay or prevent it. Skin aging usually begins around the age of 25, and skin aging proceeds in earnest at around the age of 40 years. As a representative phenomenon of skin aging, sebum secretion is reduced, skin becomes dry, cell regeneration is delayed, and aging skin is piled up and skin becomes rough. In addition, the amount of collagen that supports the epidermis is reduced, and elastin (elastic fibers) is denatured to form wrinkles. In addition, the color of the skin is stained, spots, black spots and pigmentation symptoms appear, the skin becomes thinner and the skin protection function is weakened. Other phenomena include an increase in skin troubles due to a decrease in the skin barrier effect (barrier effect) associated with a decrease in skin thickness. Researches related to skin aging are classified into materials that protect skin from ultraviolet rays and active oxygen, which are major causes of skin aging, skin wrinkle improving materials, skin elasticity enhancing materials, skin moisturizing materials, have.
피부에 노화가 진행되면 진피의 변화가 현저하게 나타나며, 70세 이후 나타나는 진피위축은 대표적인 노화현상이다. 진피의 변화는 섬유아세포(fibroblast)의 숫자와 이들의 합성 능력의 감소로 인하여 세포 외 기질 중 큰 분자량을 가진 물질들의 변화로 발생된다. 그 구체적인 변화는 콜라겐 다발의 분리, 점다당질 합성감소, 콜라겐과 탄력섬유(elastin)수와 직경 감소, 콜라겐과 탄력섬유 분쇄 및 혈관의 팽창 등을 들 수 있다. 일반적으로 피부의 수분 함유량, 콜라겐 함유량 및 외부 환경에 대한 면역작용 능력 등 여러 가지 복합적인 요인들 중 주름의 형성에 가장 큰 영향을 미치는 것은 콜라겐의 생성량과 콜라겐의 함량을 감소시키는 콜라겐 분해효소인 콜라겐 분해효소의 발현량과 활성이다. Dermatological atrophy is a typical aging phenomenon after 70 years of age. Changes in the dermis are caused by a change in the number of fibroblasts and a change in the molecular weight of the extracellular matrix due to a decrease in their ability to synthesize. Specific changes include separation of collagen bundles, reduction of point polysaccharide synthesis, reduction in the number and diameter of collagen and elastic fibers, collagen and elastic fiber grinding, and expansion of blood vessels. Generally, the most important factors affecting the formation of wrinkles among various complex factors such as moisture content of the skin, collagen content, and immunity against the external environment are collagen decomposition enzyme collagenase, which reduces collagen production and collagen content The amount and activity of digestive enzymes.
따라서, 화장품 분야에서는 피부 주름 개선효과를 가지는 기능성 화장품에 대한 연구 및 개발이 활발하게 진행되고 있으며, 특히 피부에 독성이나 자극을 주지 않기 위하여 천연 물질을 이용한 연구가 계속되고 있다.Therefore, in the field of cosmetics, research and development on functional cosmetics having the effect of improving the wrinkles of the skin are actively carried out, and studies using natural materials have been continuing in order not to give toxicity or irritation to the skin.
이에 본 발명자들은 피부 주름 개선효과 및 피부노화 방지 효과가 우수하고 안전성 및 안정성이 높아 피부 부작용이 없는 천연유래 화합물을 대상으로 개발하고자 노력하였다. 그 결과, 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반 추출물 또는 이들의 추출 발효물을 포함하는 조성물이 콜라겐 합성을 증가시키고 콜라겐 분해효소 활성을 억제할 수 있음을 확인함으로써 본 발명을 완성하였다.Accordingly, the present inventors have sought to develop a naturally occurring compound which has excellent skin wrinkle-reducing effect and skin aging-preventing effect, has high safety and stability, and has no skin side effects. As a result, it has been found that a composition comprising Sukjwanghwang, Hwanggi, green tea, peony, corn oil, Puerariae, Omija, Angelica gigantei, cinnamon, cinnamon and donal placenta extract or extract fermented products thereof increases collagen synthesis and inhibits collagenolytic enzyme activity The present invention has been completed.
따라서, 본 발명에서 해결하고자 하는 기술적 과제는 콜라겐 합성능이 우수하고, 콜라겐 분해효소 활성의 억제작용이 우수한 피부 주름 예방 또는 개선을 위한 조성물을 제공하기 위한 것이다. SUMMARY OF THE INVENTION Accordingly, it is an object of the present invention to provide a composition for preventing or improving wrinkles of a skin having excellent collagen synthesis ability and excellent collagenase activity inhibiting action.
상기한 기술적 과제를 해결하기 위하여, 본 발명에서는 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반으로 이루어진 혼합 추출물 또는 이의 발효물과 꿀 및 이의 화장학적으로 허용가능한 염을 포함하는 피부 주름 예방 또는 개선을 위한 화장료 조성물을 제공한다.In order to solve the above-mentioned technical problems, the present invention provides a mixed extract or a fermented product consisting of Sukjunghwang, Hwanggi, green tea, peony, Sansui, Pueraria, Omija, Angelica gigas, Or a pharmaceutically acceptable salt thereof, for the prevention or amelioration of skin wrinkles.
본 발명에서는 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반으로 이루어진 혼합 추출물 또는 이의 발효물과 꿀 및 이의 약학적으로 허용가능한 염을 포함하는 피부 주름 예방 또는 개선을 위한 약학적 조성물을 제공한다.In the present invention, skin wrinkles comprising a mixed extract consisting of Sukjunghwang, Hwanggi, Green tea, Peony root, Sansui, Pueraria, Omija, Angelica, Angelica, Cinnamon, Prevention or amelioration of a disease or condition.
본 발명에서는 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반으로 이루어진 혼합 추출물 또는 이의 발효물과 꿀 및 이의 식품학적으로 허용가능한 염을 포함하는 피부 주름 예방 또는 개선을 위한 식품 조성물을 제공한다.In the present invention, skin wrinkles containing mixed extracts or a fermented product thereof, honey and a pharmaceutically acceptable salt thereof, consisting of a mixture of Sukjunghwang, Hwanggi, Green tea, Peony root, Sansui, Pueraria, Omija, Angelica gigas, Prevention or amelioration.
바람직한 하나의 구현예에 따르면, 본 발명에서는 숙지황 2 내지 10 중량%, 황기 2 내지 10 중량%, 녹차 2 내지 10 중량%, 작약 2 내지 10 중량%, 산수유 1 내지 8 중량%, 갈근 1 내지 8 중량%, 오미자 1 내지 8 중량%, 당귀 0.5 내지 5 중량%, 천궁 0.5 내지 5 중량%, 계피 0.5 내지 5 중량%, 대회향 0.1 내지 2 중량%, 돈태반 1 내지 3 중량% 및 꿀 40 내지 60 중량%로 이루어진 피부 주름 예방 또는 개선을 위한 조성물을 제공한다.According to one preferred embodiment, in the present invention, 2 to 10% by weight of steamed rice, 2 to 10% by weight of sulfur, 2 to 10% by weight of green tea, 2 to 10% by weight of peanut, 1 to 8% 1 to 3% by weight of honey and 1 to 3% by weight of honey and 40 to 60% by weight of honey, 0.5 to 5% By weight of a composition for prevention or improvement of skin wrinkles.
본 발명에 있어서, "추출물"은 상기 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반 각각을 통상의 방법에 의하여 추출한 추출물로서, 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반 각각을 추출한 추출액뿐만 아니라 이의 건조 분말 또는 이를 이용하여 제형화된 모든 형태를 포함한다.In the present invention, the " extract " is an extract obtained by extracting each of the above-mentioned Sukjunghwang, Hwanggi, Green tea, Peony, Sansui, Punggi, Omija, Angelica gigas, , Peony root, corn oil, Puerariae radix, Omija, Angelicae gigantei, cinnamon, cinnamon, garlic, and donkey placenta, as well as their dry powders or all forms thereof formulated therewith.
상기 추출물은 물 또는 유기 용매를 사용하여 추출할 수 있는데, 추출한 액은 액체 형태로 사용하거나 또는 농축 및/또는 건조하여 사용할 수 있다. 상기 유기 용매는 메탄올, 에탄올, 이소프로판올, 부탄올, 에틸렌, 아세톤, 헥산, 에테르, 클로로포름, 에틸아세테이트, 부틸아세테이트, 디클로로메탄, N,N-디메틸포름아미드(DMF), 디메틸설폭사이드(DMSO), 1,3-부틸렌글리콜, 프로필렌글리콜 또는 이들의 혼합용매이며, 추출물의 유효 성분이 파괴되지 않거나 최소화된 조건에서 실온 또는 가온하여 추출할 수 있다. The extract can be extracted with water or an organic solvent, and the extracted liquid can be used in liquid form or can be used by concentration and / or drying. The organic solvent may be selected from the group consisting of methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethylsulfoxide , 3-butylene glycol, propylene glycol, or a mixed solvent thereof. The extract can be extracted at room temperature or with heating under the condition that the active ingredient of the extract is not destroyed or minimized.
하나의 구체적 실시에서, 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반의 추출물은 각각 10배 양(w/v)의 증류수를 넣어 90℃에서 4시간 추출한 후 여과지로 상층액을 회수하는 공정을 3회 반복하여 모은 후 감압건조시킴으로써 추출할 수 있다.In one specific embodiment, the extracts of Sukjwanghwang, Hwanggi, green tea, peony, Sansui, Pueraria, Omija, Angelica, Angelica, Cinnamon, After extracting the time, the process of collecting the supernatant with the filter paper is repeated 3 times, and then collected and dried under reduced pressure.
상기 추출 방법은 제한되지 않고, 예를 들어, 냉침추출, 초음파 추출, 환류 냉각 추출 등이 있다.The extraction method is not limited, and examples thereof include cold extraction, ultrasonic extraction, and reflux cooling extraction.
본 발명의 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반의 혼합 추출물은 추출, 분획, 또는 정제(분리, 분획)의 각 단계에서 얻어지는 모든 추출액, 분획, 정제물, 그들의 희석액, 농축액, 또는 건조물일 수 있다.The mixed extracts of the present invention of the present invention can be obtained by extracting all extracts obtained in each step of extraction, fractionation, or purification (separation, fractionation) Fraction, purified product, diluted solution thereof, concentrated solution, or dried product.
또한, 본 발명에서는 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향의 추출부위는 줄기, 뿌리, 잎, 꽃 등 모든 부위를 사용할 수 있으며, 특히 뿌리가 바람직하나, 어느 특정 부위로 한정되지 않는다.In the present invention, all parts such as stem, root, leaf, and flower can be used as extraction sites of Sukjunggwang, Hwanggi, Green tea, Peony root, Sansui, Puerariae, Omija, , And is not limited to any specific site.
본 발명에 있어서, "추출 발효물"은 상기 추출물을 유산균 중에서 발효한 것을 의미한다. 이 때 발효균으로 유산균을 사용하며, 예를 들어, 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 플란타룸(L. plantarum), 락토바실러스 애시도필러스(L. acidophilus), 락토바실러스 불가리쿠스(L.bulgaricus), 비피도박테리움 롱굼(Bifidobacterium longum), 비피도박테리움 비피둠(B. bifidum) 또는 이들의 혼합균을 사용할 수 있으며, 바람직하게는 락토바실러스 플란타룸(L. plantarum), 비피도박테리움 비피둠(B. bifidum) 또는 이들의 혼합균을 사용할 수 있으며, 특히 락토바실러스 플란타룸(L. plantarum) 및 비피도박테리움 비피둠(B. bifidum)이 바람직하다. In the present invention, " extracted fermented product " means that the extract is fermented in lactic acid bacteria. In this case, lactic acid bacteria are used as the fermenting bacteria, for example, Lactobacillus casei casei, L. plantarum , L. acidophilus , L. bulgaricus , Bifidobacterium longum , Bifidobacterium, Bifidobacterium longum , Bifidobacterium longum , B. bifidum or a mixed microorganism thereof may be used. Preferably, L. plantarum, B. bifidum or a mixed microorganism thereof can be used. And L. plantarum and B. bifidum are particularly preferable.
본 발명의 바람직한 구현예에서, 추출 발효물은 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반의 혼합 추출물에 유산균을 추출물 중량을 기준으로 4 내지 6 중량%의 양으로 접종하여 10 내지 20시간 동안 배양하여 제조될 수 있다.In a preferred embodiment of the present invention, the fermented extract is prepared by adding lactic acid bacterium to a mixed extract of Sukjunghwang, Hwanggi, Green tea, Peony, Sansui, Pueraria, Omija, Angelica, By weight, and incubating for 10 to 20 hours.
본 발명의 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반으로 이루어진 혼합 추출물 또는 이의 발효물과 꿀 또는 이의 화장학적, 약학적 또는 식품학적으로 허용가능한 염을 유효성분으로 포함하는 피부 주름(skin wrinkle) 개선용 조성물은 피부 노화 방지 또는 피부 주름 개선의 용도를 가진다. The mixed extract of the present invention or a fermented product thereof and honey or its cosmetic, pharmacologically or pharmacologically acceptable extracts of the present invention, A composition for improving skin wrinkles containing a salt as an active ingredient has a use for preventing skin aging or improving skin wrinkles.
본 발명의 조성물은 세포독성도 낮으면서도, 콜라겐 합성의 촉진 기전 및 콜라겐 분해효소 억제활성을 통하여 우수한 주름 개선 효능을 발휘하며, 이는 하기의 실시 예에 의해 명확하게 확인된다. The composition of the present invention exhibits an excellent wrinkle-reducing effect through the promoting mechanism of collagen synthesis and collagenase inhibiting activity while being low in cytotoxicity, which is clearly confirmed by the following examples.
본 발명의 조성물의 용도인 피부 주름 개선은 통상적인 피부 보호용도(주름의 예방, 주름의 제거, 예방 또는 치료 등)를 포함하는 것으로 해석된다.The improvement in skin wrinkles, which is the application of the composition of the present invention, is interpreted to include conventional skin protection uses (prevention of wrinkles, removal of wrinkles, prevention or treatment, etc.).
본 발명의 구체적인 실시양태에서는 일반적으로 주름개선 물질 스크리닝에 이용되는 콜라겐 생합성, 콜라겐 분해효소 활성 억제능 등을 측정한다. 그 결과 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반으로 이루어진 혼합 추출물 또는 이의 발효물과 꿀을 포함하는 조성물은 콜라겐 생성과 세포 증식을 촉진할 뿐만 아니라 콜라겐 분해효소 활성도 억제시키는 효과를 관찰할 수 있다.In a specific embodiment of the present invention, collagen biosynthesis, collagenase activity inhibitory activity and the like, which are generally used for screening wrinkle-reducing substances, are measured. As a result, a composition comprising a mixed extract consisting of Sukjunghwang, Hwanggi, green tea, peony, Sansui, Pueraria, Omija, Angelica, Angelica, Cinnamomum, Convolvulus and Don placenta or a fermented product thereof and honey has the advantages of promoting collagen production and cell proliferation But also the effect of inhibiting collagenase activity can be observed.
본 발명의 조성물의 유효성분인 숙지황은 지황(Rehmannia glutinosa Liboschitz var. purpurea Makino 또는 R. glutinosa Liboschitz)의 뿌리를 가공한 것으로, 혈액 결핍 및 이에 따른 간과 심장의 영양 부족의 치료를 위해 사용되고, 또한 간과 신장의 음을 강하게 하는 것으로 알려져 있다. 이러한 간과 심장의 영양 부족에 따라 등 통증, 어지럼증, 현기증, 이명, 청력감퇴, 주기적인 발열, 식은땀 등의 증상이 나타난다. 숙지황은 충(중국어로는 jing, 영어로는 essence)을 보충하고, 뼈골을 채우는 것으로 알려져 있고, 신장의 영양결핍에 따른 헛기침, 천명, 천식 등을 경감시킬 수 있다고 알려진다. 이와 같이 기존에 숙지황에 대한 몇몇 효과가 알려져 있으나, 콜라게나제 활성 저해효과에 대한 효과에 대한 연구는 이루어지지 않았다.The active ingredient of the composition of the present invention, rosewood, is the root of Rehmannia glutinosa Liboschitz var. Purpurea Makino or R. glutinosa Liboschitz . It is used for the treatment of blood deficiency and consequently liver and heart malnutrition, It is known to strengthen the height of the kidneys. Symptoms such as back pain, dizziness, dizziness, tinnitus, hearing loss, periodic fever, and cold sweating may occur due to lack of nutrition of the liver and heart. It is known that it is supplemented with jing (jing in Chinese, essence in English), filling the bone, and it is known that it can alleviate vomiting, wheezing, asthma by the nutritional deficiency of the kidney. Thus, although some effects have been known in the past, there has been no study on the effect of inhibiting collagenase activity.
본 발명의 조성물의 유효성분인 황기(Astragalusmembranaceus Bunge)는 산지에서 자라며 높이가 1m에 달하고 전체에 잔털이 있다. 잎은 6∼11쌍의 소엽으로 구성된 기수1회우상복엽이다. 꽃은 7, 8월에 피고 길이 15 ∼ 18 ㎜로서 연한 황색이며 긴 꽃대에 여러 개의 꽃이 어긋나며 피는 꽃차례를 이룬다. 뿌리는 약재로 이용하는데 약효성분은 폴리산(folic acid)ㅇ콜린(choline) 등이다. 동물실험에서는 중추신경계통의 흥분작용과 이뇨작용도 현저하였으며, 흰쥐에게 대량의 분말을 투여하였을 때에는 신염의 발생을 억제 시키고 단백뇨와 콜레스테롤혈증의 발생도 지연시켰으며, 혈압강하작용도 인정되었다. 또한, 자궁하수, 위하수, 탈홍, 자궁출혈에도 널리 이용되며, 체력을 항진시켜 주고 전신 근육의 긴장도를 높여주기도 한다.The active ingredient of the composition of the present invention, Astragalus semblanaceus Bunge , grows in the mountain area, reaches a height of 1m and has fine hairs throughout. Leaves are 6 ~ 11 pairs of lobes, and are odd-numbered birds. Flowers bloom in July and August, 15 ~ 18 ㎜ in length, light yellow, and several flowers hang on a long peduncle, forming a bloom. Root is used as a medicinal ingredient, and its active ingredient is folic acid, choline, and the like. In animal experiments, the excitatory and diuretic effects of the central nervous system were also remarkable. When a large amount of powder was administered to rats, the occurrence of nephritis was inhibited, the proteinuria and cholesterolemia were delayed, and the hypotensive effect was also recognized. It is also widely used for uterine drainage, gastrointestinal tract, gastrointestinal tract, esophagus, and uterine bleeding. It also increases physical strength and increases the tension of whole body muscles.
본 발명의 조성물의 유효성분인 녹차는 차나무(Camellia sinensis)의 잎을 원료로 사용한다. 새로 돋은 가지에서 딴 어린잎을 차 제조용으로 사용하고 대개 5월, 7월, 8월 세 차례에 걸쳐 잎을 따며 5월에 딴 것이 가장 좋은 차가 된다. 이 차나무는 상록수로 비교적 따뜻하고 강우량이 많은 지역에서 잘 자란다. 녹차를 제조하려면 딴 잎을 즉각 가열하여 산화효소를 파괴시켜 녹색을 그대로 유지하는 동시에 수분을 증발시켜 잎이 흐늘흐늘하게 하여 말기 좋은 상태로 만든다. 근래에는 증열기, 조유기, 유염기, 재건기, 정유기, 건조기 등을 사용하여 차를 제조한다.Green tea, which is an active ingredient of the composition of the present invention, uses leaves of Camellia sinensis as a raw material. The young leaves from the newly bloomed branches are used for tea making, and the leaves are usually picked up three times in May, July and August and the best tea in May is the one. This tea is an evergreen tree that grows well in relatively warm and rainfall areas. In order to produce green tea, the other leaf is immediately heated to destroy the oxidizing enzyme to keep the green, while at the same time evaporating the water to make the leaves dull and cloudy. In recent years, cars are manufactured using steam boilers, crude oil generators, oil boilers, rebuilders, vacuum cleaners, and dryers.
본 발명의 조성물의 유효성분인 작약(芍藥, Paeonialactiflora)은, 쌍떡잎식물 작약과 작약속의 여러해살이풀로서, 높이는 1m 내외이고, 꽃 색깔에 따라 백작약 또는 적작약으로 나누기도 한다. 작약에는 아스파라긴산과 안식향산등의 성분이 함유되어 있어, 두통이나 치통을 가라앉혀준다. 또한 체내의 어혈을 제거하고 혈액순환을 원활하게 하여 피를 맑게 해주고 여성질환의 개선에도 효과가 있으며, 작약을 꾸준히 복용하면 위산의 분비를 억제시키면서 위장을 이완시켜 위경련이나 위궤양을 완화시키고, 신경통 또는 복통 등에도 효과가 있다.Paeonialactiflora, an active ingredient of the composition of the present invention, is a perennial herb that is a perennial herbaceous herbaceous plant of peonies and peonies. It is about 1m in height and may be divided into a white seed or an apple depending on the flower color. Peony contains ingredients such as aspartic acid and benzoic acid, and headache and toothache to settle. In addition, it eliminates the blood in the body, smoothes the blood circulation, cleanses the blood and is effective for the improvement of the female disease. When taking the peony pills steadily, the stomach is relaxed while suppressing the secretion of stomach to relieve stomach cramps and stomach ulcers. It is also effective for abdominal pain.
본 발명의 조성물의 유효성분인 산수유(Cornus officinalis)는 층층나무과의 낙엽교목인 산수유나무의 열매이다. 타원형의 핵과(核果)로서 처음에는 녹색이었다가 8~10월에 붉게 익는다. 종자는 긴 타원형이며, 능선이 있다. 약간의 단맛과 함께 떫고 강한 신맛이 난다. 10월 중순의 상강(霜降) 이후에 수확하는데, 육질과 씨앗을 분리하여 육질은 술과 차 및 한약의 재료로 사용한다. 과육(果肉)에는 코르닌(cornin), 모로니사이드(Morroniside), 로가닌(Loganin), 타닌(tannin), 사포닌(Saponin) 등의 배당체와 포도주산, 사과산, 주석산 등의 유기산이 함유되어 있고, 그밖에 비타민 A와 다량의 당(糖)도 포함되어 있다. 종자에는 팔미틴산, 올레인산, 리놀산 등이 함유되어 있다. 성분 중 코르닌은 부교감신경의 흥분작용이 있는 것으로 알려져 있다. 예로부터 한방에서는 과육을 약용하였다. "동의보감" "향약집성방" 등에 의하면 강음(强陰), 신정(腎精)과 신기(腎氣)보강, 수렴 등의 효능이 있다고 한다. 두통, 이명(耳鳴), 해수병, 해열, 월경과다 등에 약재로 쓰이며 식은땀, 야뇨증 등의 민간요법에도 사용된다. 차나 술로도 장복하며, 지한(止汗), 보음(補陰) 등의 효과가 있다. 산수유나무는 한국, 중국 등이 원산으로, 한국의 중부 이남에서 심는다. 국내에서는 전라남도 구례군 산동면과 경기도 이천시 백사면 일원, 경상북도 의성군 등에서 특산품으로 매년 출하하고 있다. Cornus officinalis ( Cornus officinalis ), an active ingredient of the composition of the present invention, is a fruit of the saponin tree which is a deciduous tree in the deep forest. Elliptical nuclei are green at first, but ripen reddish from October to October. Seeds are long oval and have ridges. It has a bitter sweetness and strong acidity. It is harvested after the frost fall in mid-October. The flesh is separated from the seeds and the meat is used as a material for sake, tea and Chinese medicine. The pulp contains the glycosides such as cornin, morroniside, loganin, tannin and saponin and organic acids such as wine, malic and tartaric acid. In addition, it contains vitamin A and a large amount of sugars. Seeds include palmitic acid, oleic acid, linoleic acid, and the like. Among the components, cornin is known to have an excitatory action of parasympathetic nerves. From the past, the pulp was weakened in one batch. According to the "Dongbibogam" and the "Fragrant Bulgari", it is said that it has effects such as strengthening of 阴 阴, 肾 精 and 肾气, and convergence. It is used for medicines such as headache, tinnitus, blood circulation, fever, and menstrual hyperactivity. It is also used for folk remedies such as cold sweat and enuresis. It can also be used as a tea or a drink, and has effects such as stopping sweat and consonant. Sansui is native to Korea and China, and is planted in the middle of South Korea. In Korea, Shandong, Gyeonggi Province, Gyeonggi Province, Gyeonggi Province, and Gyeongsangbukdo, Yusung Gun, and other local products are shipped every year.
본 발명의 조성물의 유효성분인 갈근(葛根, Puerariae Radix)은 콩과 식물의 다년생 초본인 칡(野葛, Pueraria lobata Ohwi)의 뿌리를 건조시킨 것으로 한국, 중국, 일본 각 지역의 산에 자생한다. 한의학에서는 칡의 여러 부위를 각각 분류하여, 칡 뿌리를 건조한 것을 갈근, 꽃은 갈화, 열매는 갈곡 또는 갈실, 잎은 갈엽, 덩굴은 갈만이라 부르며 질병의 증상 및 치료방법에 따라 각각 다르게 사용하여 왔다. 한방에서 갈근은 기육을 풀어 주는 작용을 하므로 감기 몸살이나 발진성 질환, 항강통(項强痛) 등에 해표 시킬 목적으로 사용되며, 비장과 위장의 기를 상승하게 도와주어 진액을 만들어 갈증을 해소하게 하고 지사 시키는 작용을 한다.The active ingredient of the composition of the present invention, Puerariae Radix , is a dried perennial plant of Pueraria lobata Ohwi , a perennial herb of soybean plants and is grown in mountains of Korea, China and Japan . In Oriental medicine, the various parts of 칡 are classified respectively, and the dried root is called as Pueraria, the flower is Galána, the fruit is Galák or Galil, the leaf is called elliptical, and the vine is called Galáman. . It is used for the purpose of releasing cold muscle, digestive diseases, epigastric diseases, and so on. It helps the spleen and stomach to rise, so it can help to relieve thirst It acts as a branch office.
본 발명의 조성물의 유효성분인 오미자(Schisandra chinensis)는 공 모양으로 지름 약 1cm이고 짙은 붉은 빛깔이다. 속에는 붉은 즙과 불그스레한 갈색 종자가 1∼2개 들어 있다. 단맛, 신맛, 쓴맛, 짠맛, 매운맛의 5가지 맛이 나며 그 중에서도 신맛이 강하다. 종류에는 오미자(북오미자), 남오미자, 흑오미자 등이 있다. 오미자는 주로 태백산 일대에 많이 자라고 남오미자는 남부 섬지방, 흑오미자는 제주도에서 자란다. 한국을 비롯하여 일본, 사할린섬, 중국 등지에서 생산한다. 시잔드린, 고미신, 시트럴, 사과산, 시트르산 등의 성분이 들어 있어 심장을 강하게 하고 혈압을 내리며 면역력을 높여 주어 강장제로 쓴다. 폐 기능을 강하게 하고 진해, 거담 작용이 있어서 기침이나 갈증 등을 치료하는 데 도움이 된다. 말린 열매를 찬물에 담가 붉게 우러난 물에 꿀, 설탕을 넣어 음료로 마시거나 화채나 녹말편을 만들어 먹는다. 밤, 대추, 미삼을 함께 넣고 끓여 차를 만들거나 술을 담그기도 한다. Schisandra chinensis , an active ingredient of the composition of the present invention, has a ball shape with a diameter of about 1 cm and a deep red color. It contains 1-2 drops of red juice and reddish brown seeds. There are five flavors of sweetness, sourness, bitter taste, salty taste and spicy taste, among which the sour taste is strong. There are two types of omija (north omija), south omija, and black omija. Omiza grows mainly in the area of Taebaek Mountain, Namimiza grows in the southern island region, and black omija grows in Jejudo. It is produced in Korea, Japan, Sakhalin, and China. It contains ingredients such as thiazide, thymidine, citrulline, malic acid, and citric acid, which strengthens the heart, lowers the blood pressure, increases immunity, and is used as a tonic. It strengthens the pulmonary function, and it helps to cure the cough and thirst by the deep sea bream and the geodam function. It puts dried fruit in cold water and puts honey and sugar in the water which is reddish, and drinks it with a drink, and it makes it to eat a leaf or a starch piece. Chestnuts, jujube, and mushrooms are put together and boiled to make tea or soak.
본 발명의 조성물의 유효성분인 당귀(Angelica Gigas)는 미나리과에 속하며, 오장육부를 건강하게 하고 몸을 따스하게 하는 성질이 있어, 당귀의 몸통은 피를 조절하며 당귀의 윗부분은 보혈을 하는 효능이 있다. Angelica Gigas , an active ingredient of the composition of the present invention, belongs to the fauna of the persimmon, and has the property to make the five healthy and warm the body, and the body of Angelica gigas regulates blood and the upper part of angiosperms has the effect of blood .
본 발명의 조성물의 유효성분인 천궁(Cnidium officinale)은 미나리과의 다년생 초본으로 높이가 40~70㎝이고 향기가 나는 식물로서, 상처치료, 피부 재생 및 향균 작용을 한다. 또한, 멜라노사이트 자극 호르몬 활성 저해효과가 뛰어나 미백효과가 우수하다.The active ingredient of the composition of the present invention, Cnidium officinale , is a perennial herbaceous perennial herbaceous plant having a height of 40 to 70 cm and is a fragrant plant. It has wound healing, skin regeneration and antibacterial action. In addition, it excellently inhibits melanocyte stimulating hormone activity and is excellent in whitening effect.
본 발명의 조성물의 유효성분인 계피는 우리나라에서는 녹나무과의 육계(Cinnamomumcassia Blume: 肉桂) 또는 동속 근연식물의 수피 또는 주피를 다소 제거한 수피를 말한다. 육계나무는 중국의 남부지방에서 자생하는 늘푸른큰키나무로 여름부터 가을 사이에 나무껍질을 채취하여 사용한다. 이 약은 특이한 냄새가 있으며 나중에는 약간 점액성이고 수렴성이며 맛은 맵고 달며 성질은 뜨겁다. 계피는 혈액순환을 촉진시켜 흉복부의 냉증을 제거하며 식욕을 증진시키고 소화를 촉진하며 사지마비 등에 사용된다. 약리작용으로 개선균 억제작용, 백색염주균병 억제작용, 건위작용, 타액 및 위액 분비촉진작용 등이 보고되었다. Cinnamon, an active ingredient of the composition of the present invention, refers to a bark of Cinnamomum cassia Blume (broiler) or a bark of bamboo flora or flounder, which has been somewhat removed. Broiler tree is an evergreen large tree native to southern China. It is used to collect bark from summer to autumn. It has a peculiar smell and later is slightly mucilage, astringent, flavorless, sweet and temperate. Cinnamon promotes blood circulation, eliminates the coldness of the thighs, promotes appetite, promotes digestion, and is used for limb paralysis. It has been reported that the pharmacological action is to inhibit improving bacteria, to inhibit white spore strain, to act on the surface, and to stimulate saliva and gastric secretion.
본 발명의 조성물의 유효성분인 대회향은 회향(Foeniculum vulgare), 일명 팔각회향(Illicium verum)과 주요성분들이 같으며, 목련과 상록수의 열매를 말한다. 이 열매를 건조한 후 분말형태로 만든 후 향신료로 이용한다. 오리나 돼지고기를 이용한 요리 중 찜이나 조림처럼 오래 조리하는 요리에 첨가하면 주재료의 나쁜 냄새를 제거하면서 독특한 향으로 요리의 맛을 살리는 역할을 한다. 그리고 이뇨작용과 식욕증진 작용과 복부 팽만감이나 구역질을 완화하는 작용이 있다. 중국에서는 요통, 변비, 방광염의 치료에 생약으로 쓰며, 산통이나 급성 류머티스의 통증을 완화할 때에도 쓰고 있다. 또 기침약의 맛을 낼 때도 쓴다. The active ingredient of the composition of the invention is the daehoehyang fennel (Foeniculum vulgare ), aka Illicium verum, and the fruit of magnolia and evergreen. This fruit is dried and then powdered and used as a spice. When added to a dish cooked for a long time, such as steamed or simmered in a dish made with duck or pork, it is used to eliminate the bad smell of the main ingredients and to make the taste of the dish taste unique. And diuretic and appetite-promoting action, and abdominal bloating and nausea. In China, it is used as a herbal medicine for the treatment of back pain, constipation, and cystitis, and is used to alleviate pain in acupuncture and acute rheumatism. I also use it to taste cough medicine.
본 발명의 조성물의 유효성분인 돈태반(돼지 태반)은 포유류의 태반 중에서도 인태반의 분자 구조와 놀라울 정도로 흡사한 것으로 밝혀졌는데, 돈태반은 프로테인과 각종 영양소 그리고 DNA와 RNA의 중요성분으로서 세포의 차별화와 태아의 발달을 관장하는 Bio-Active cytosin의 근원으로 보고된 바 있다.The donor placenta (the placenta of the pig), which is the active ingredient of the composition of the present invention, was found to be surprisingly similar to that of the human placenta among mammalian placentas. The donor placenta is an important component of proteins and various nutrients and DNA and RNA. It has been reported as a source of Bio-Active cytosine which is responsible for differentiation and fetal development.
태반(placenta)은 임신한 포유류의 자궁에 생기는 기관으로 탯줄을 통하여 태아에게 영양분을 공급하고, 생명을 지탱하게 한다. 태반은 출산시 자궁으로부터 배출되며, 태반이 나오는 것을 후출산이라고 한다. 태반에는 필수 아미노산, 멜라토닌, RNA, DNA 등의 핵산 성분, 항산화 효소인 SOD(Super Oxide Dismutase). 히알루론산(Hyaluronic acid), 항산화제, 면역보조인자(cytocine), 태반펩타이드, 인슐린유사 성장촉진인자(insulin-like-growth factor), 표피성장촉진인자(EGFS, Epidermal Growth factors) 및 독특한 노쇠세포활성인자(SCAFS, Senescent Cell Adivating Factors) 등의 성장인자와 사이토카인 류가 포함되어 있어 피로회복, 면역증강 등에 유용한 것으로 알려져 있다. 또한, 태반은 티로신으로부터 멜라닌 과립 생성을 촉진하는 효소 티로시나아제의 활성을 저해하는 효과가 있어 색소 형성을 억제함과 동시에 멜라닌색소를 포함하는 세포의 배출을 촉진하는 작용을 발휘하여 기미의 예방과 개선에도 효과가 있으며, 결국 색소 침착을 예방하는 작용뿐만 아니라 미백작용도 나타내게 된다 (Mallick S et el., Pigment Cell Res. Feb 18(1), 25-33, 2005). 또한, 태반의 조직대사 촉진작용이 피지의 분비선 기능을 높여 피지의 분비를 정상화한 결과 잔주름을 줄이거나 제거하는 작용을 한다. 아울러, 태반에는 섬유아세포의 증식인자(FGF)가 포함되어 있어 섬유아세포의 증식, 재생을 촉진하며 이의 활성화를 통해 콜라겐, 엘라스틴, 히알루론산의 양을 증가시켜 피부의 신축성이나 탄력성을 회복하여 깊은 주름과 피부처짐을 개선시키는 작용을 하게 된다. The placenta is an organs in the uterus of a pregnant mammal, which feeds the fetus through the umbilical cord and sustains life. The placenta is released from the uterus at birth, and the placenta is called postnatal. The placenta contains essential amino acids, melatonin, RNA, DNA and other nucleic acid components, and the antioxidant enzyme SOD (Super Oxide Dismutase). It has been shown to be effective in the treatment of various diseases such as hyaluronic acid, antioxidants, cytocines, placental peptides, insulin-like-growth factor, epidermal growth factors (EGFS) (SCAFS, Senescent Cell Adivating Factors) and cytokines are known to be useful for restoring fatigue and improving immunity. In addition, the placenta has an effect of inhibiting the activity of enzyme tyrosinase, which promotes melanin granulation from tyrosine, thereby inhibiting pigment formation and promoting the release of cells containing melanin pigment, (Mallick S et al., Pigment Cell Res. Feb 18 (1), 25-33, 2005), as well as the effect of preventing pigmentation. In addition, the placenta promotes the action of tissue metabolism by increasing sebaceous gland function to normalize the secretion of sebum, the effect is to reduce or eliminate the fine lines. In addition, the placenta contains fibroblast growth factor (FGF), which promotes the proliferation and regeneration of fibroblasts. Through its activation, it increases the amount of collagen, elastin, and hyaluronic acid, restoring the elasticity and elasticity of the skin, And to improve skin deflection.
태반의 추출 방법으로는, 종래에 강산(보통 3N 염산)이나 강알칼리를 이용하여 태반을 가수분해하여 그 산물을 얻는 방법이나, 효소를 이용한 태반 추출 방법 등이 이용되어 왔다. 한국 공개특허 제10-2007-0004477호에서는 알칼리 가수분해를 통해 태반 추출물을 제조하는 방법을 기술하고 있으며, 한국 등록특허 제0642080호에서는 식물효소 및 산 가수분해를 통해 태반 추출물을 제조하는 방법을 기술하고 있고, 일본공개특허 제2004-097033호에서는 단백분해효소를 이용한 태반 추출물의 제조 방법을 기술하고 있으며, 한국 등록특허 제0642681호에서는 초임계 추출법(supercritical fluid extraction process)을 이용한 태반 추출물의 제조 방법을 기술하고 있다. As a method of extracting placenta, conventionally, a method of hydrolyzing placenta using strong acid (usually 3N hydrochloric acid) or strong alkali to obtain the product, and placenta extraction method using enzyme have been used. Korean Patent Laid-Open No. 10-2007-0004477 describes a method for producing placenta extract through alkaline hydrolysis. In Korean Patent No. 0642080, a method for producing a placenta extract through plant enzyme and acid hydrolysis is described Japanese Patent Laid-Open Publication No. 2004-097033 describes a method for preparing a placenta extract using proteolytic enzyme. In Korean Patent No. 0642681, a method for producing a placenta extract using a supercritical fluid extraction process .
본 발명의 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반으로 이루어진 혼합 추출물 또는 이의 발효물과 꿀 또는 이의 화장학적, 약학적 또는 식품학적으로 허용가능한 염을 함유하는 조성물은 피부 주름 개선효과를 나타내며, 천연 물질로서 세포독성이 거의 없다. The mixed extract of the present invention or a fermented product thereof and honey or its cosmetic, pharmacologically or pharmacologically acceptable extracts of the present invention, The composition containing the salt exhibits an effect of improving skin wrinkles, and has little cytotoxicity as a natural substance.
본 발명의 하나의 실시양태에 따르면, 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반으로 이루어진 혼합 추출물 또는 이의 발효물과 꿀 또는 이의 화장학적으로 허용가능한 염을 유효성분으로 포함하는 화장료 조성물을 제공한다.According to one embodiment of the present invention, there is provided a cosmetic composition comprising a mixed extract consisting of Safflower, Hwanggi, green tea, peony, corn oil, Puerariae, Omija, Angelica gigas, A cosmetic composition comprising a salt as an active ingredient is provided.
본 발명의 바람직한 구현예에서, 상기 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반으로 이루어진 한약재 추출물 또는 이의 발효물과 꿀은 전체 조성물을 기준으로 하여 0.00001 내지 15.0 중량%, 보다 바람직하게는 0.0001 내지 10 중량%, 가장 바람직하게는 0.0001 내지 5 중량%의 양으로 포함될 수 있다. In a preferred embodiment of the present invention, the medicinal herb extract or its fermented product and honey, which comprise the medicinal plant extract of Sukkiwanghae, Huanggi, Green tea, Peony root, Sansui, Pueraria, Omija, Angelica gigas, May be contained in an amount of 0.00001 to 15.0 wt%, more preferably 0.0001 to 10 wt%, and most preferably 0.0001 to 5 wt%.
본 발명의 하나의 실시양태에 따른 화장료 조성물에는 유효성분 이외에 화장품 조성물에 통상적으로 첨가되는 성분, 예컨대 항산화제, 안정화제, 가용화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 및 담체를 추가로 첨가할 수 있다. The cosmetic composition according to one embodiment of the present invention may contain, in addition to the active ingredient, conventional additives such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavoring agents, Can be added.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 영양 크림, 수렴 화장수, 유연 화장수, 로션, 에센스, 영양젤 또는 마사지 크림의 제형으로 제조될 수 있다.The cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be prepared as a nutritional cream, a convergent lotion, a soft lotion, a lotion, an essence, a nutritional gel or a massage cream.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트 검, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, use is made of an animal oil, vegetable oil, wax, paraffin, starch, tragacanth gum, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, tosse, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, chlorofluorohydrocarbons, propane / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 가용화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 검등이 이용될 수 있다.In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Castellulose, aluminum metahydroxide, bentonite, agar or tracert, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.
본 발명의 하나의 실시양태에 따른 약학적 조성물은 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반으로 이루어진 혼합 추출물 또는 이의 발효물 이외에 약학적으로 허용되는 담체를 포함한다. 본 발명의 약학적 조성물에 포함되는 약학적으로 허용되는 담체는 제제 시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. 적합한 약제학적으로 허용되는 담체 및 제제는 Remington's Pharmaceutical Sciences (19th ed., 1995)에 상세히 기재되어 있다.The pharmaceutical composition according to one embodiment of the present invention is pharmaceutically acceptable in addition to mixed extracts or fermented products thereof consisting of Sukjunghwang, Hwanggi, Green tea, Peony, Sansui, Pueraria, Omija, Angelica, . The pharmaceutically acceptable carrier to be contained in the pharmaceutical composition of the present invention is one usually used at the time of formulation, and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc., in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약학적 조성물은 경구 또는 비경구 투여할 수 있으며, 바람직하게는 비경구 투여, 보다 바람직하게는 도포에 의한 국부 투여(topical application) 방식으로 적용된다.The pharmaceutical composition of the present invention can be administered orally or parenterally, and is preferably applied by parenteral administration, more preferably topical application by application.
본 발명의 약학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성별, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. 본 발명의 약학적 조성물의 투여량은 성인 기준으로 0.001-100 ㎎/kg 범위 내이다. 또한 외용제인 경우에는 성인 기준으로 1.0 내지 3.0 ml의 양으로 1일 1회 내지 5회 도포하여 1개월 이상 계속 하는 것이 좋다. 다만, 상기 투여량은 본 발명의 범위를 한정하는 것이 아니다.A suitable dosage of the pharmaceutical composition of the present invention may vary depending on such factors as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, route of administration, excretion rate, . The dosage of the pharmaceutical composition of the present invention is in the range of 0.001-100 mg / kg on an adult basis. When the composition is an external preparation, it is preferably applied in an amount of 1.0 to 3.0 ml on an adult basis once to five times a day, and continued for 1 month or more. However, the dose is not intended to limit the scope of the present invention.
본 발명의 약학적 조성물은 당분야의 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이 때 제형은 오일 또는 수성 매질중의 용액, 현탁액, 시럽제 또는 유화액 형태이거나 엑시르제, 산제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention may be prepared in unit dosage form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art, Into the container. The formulations may be in the form of solutions, suspensions, syrups or emulsions in an oil or aqueous medium, or in the form of excipients, powders, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
또한, 본 발명의 하나의 실시양태에 따른 식품 조성물에는 유효성분으로서 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반으로 이루어진 혼합 추출물 또는 이의 발효물과 꿀뿐만 아니라 식품 제조 시에 통상적으로 첨가되는 성분, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 추가로 포함할 수 있다.In addition, the food composition according to one embodiment of the present invention may contain, as an active ingredient, a mixed extract consisting of Sukjibo, Huanggi, Green tea, Peony, Sansui, Pueraria, Omija, Angelica, Angelica, Cinnamon, For example, proteins, carbohydrates, fats, nutrients, flavoring agents and flavors, which are conventionally added in the manufacture of food, as well as honey.
상기 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다.Examples of such carbohydrates are monosaccharides, such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings.
예컨대, 본 발명의 식품 조성물이 드링크제로 제조되는 경우에는 본 발명의 잠사 추출물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액, 감초 추출액 등을 추가로 포함시킬 수 있다.For example, when the food composition of the present invention is prepared as a drink, it may further contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, have.
한편, 본 발명의 조성물의 유효성분인 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반으로 이루어진 혼합 추출물 또는 이의 발효물과 꿀은 인체에 무해하며, 독성 및 부작용이 거의 없으므로 장기간 사용시에도 안심하고 사용할 수 있으며, 특히 상기한 바와 같은 화장료, 약학적 및 식품 조성물에 안전하게 적용할 수 있다.On the other hand, the mixed extracts of the active ingredients of the composition of the present invention, namely, Sukjunggwang, Hwanggi, Green tea, Peony, Sansui, Pueraria, Omija, Angelica gigas, Toxicity and side effects, it can be safely used even in long-term use, and can be safely applied to cosmetic, pharmaceutical and food compositions as described above.
이와 같이, 본 발명의 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반으로 이루어진 한약재 추출물 또는 이의 발효물과 꿀 및 이의 화장학적, 약학적 또는 식품학적으로 허용가능한 염을 유효성분으로 포함하는 조성물은 콜라겐 생합능이 우수하고, 콜라겐 분해효소 억제효과가 우수하여 피부 주름 개선효과를 가진다. 또한, 본 발명의 피부 주름 예방 또는 개선을 위한 조성물의 유효성분인 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반으로 이루어진 한약재 추출물 또는 이의 발효물과 꿀은 세포 독성 및 피부 부작용이 없어 화장료 조성물, 약학적 조성물 및 식품 조성물에 안전하게 사용할 수 있다. As described above, the herbal medicine extract, the fermented product thereof, the honey, and the cosmetic, pharmaceutical or foodstuffs of the present invention comprising medicinal plant extracts, medicinal plants extracts of the present invention, green tea, peonies, As an active ingredient, is excellent in collagen biosynthesis, has excellent collagenase inhibiting effect, and has an effect of improving skin wrinkles. The present invention also relates to a medicinal herb extract or its fermented product comprising the active ingredients of a composition for preventing or improving skin wrinkles, such as Sukjunghwang, Hwanggi, Green tea, Peony, Sansui, Punggi, Omija, Angelica gigas, Honey has no cytotoxicity and skin side effects and can be safely used in cosmetic compositions, pharmaceutical compositions and food compositions.
본 명세서에 첨부되는 다음의 도면들은 본 발명의 바람직한 실시예를 예시하는 것이며, 전술한 발명의 내용과 함께 본 발명의 기술사상을 더욱 이해시키는 역할을 하는 것이므로, 본 발명은 그러한 도면에 기재된 사항에만 한정되어 해석되어서는 아니 된다.
도 1은 본 발명에 따른 조성물의 콜라겐 생합성능을 측정하여 나타낸 그래프이다.
도 2는 본 발명에 따른 조성물의 콜라겐 분해효소 억제효과를 측정하여 나타낸 그래프이다.
도 3은 내지 도 5는 본 발명에 따른 한약재 추출물을 포함하는 음료의 주름 개선효과를 나타낸 임상 사진이다. BRIEF DESCRIPTION OF THE DRAWINGS The accompanying drawings, which are incorporated in and constitute a part of the specification, illustrate exemplary embodiments of the invention and, together with the description of the invention, It should not be construed as limited.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a graph showing the collagen biosynthesis performance of the composition according to the present invention.
FIG. 2 is a graph showing measured collagenase inhibitory effects of the composition of the present invention. FIG.
FIG. 3 through FIG. 5 are clinical photographs showing the effect of improving the wrinkles of beverages containing the medicinal herb extract according to the present invention.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다. Hereinafter, embodiments of the present invention will be described in detail to facilitate understanding of the present invention. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the invention are provided to more fully describe the present invention to those skilled in the art.
<실시예 1> 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반의 추출물을 포함하는 조성물의 제조Example 1 Preparation of a Composition Containing Extracts of Sukjunghwang, Hwanggi, Green Tea, Peony, Corn Starch, Puerariae Radix, Omija, Angelica, Astragalus, Cinnamon,
건조한 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반 각각을 10배 양(w/v)의 증류수를 넣어 90℃에서 4시간 추출한 후 여과지로 상층액을 회수하였다. 이러한 과정을 3회 반복하여 모은 후 감압건조시켜 -20℃에 보관하였다. (W / v) of distilled water was added to each of the extracts and dried at 90 ° C for 4 hours, and then the supernatant was filtered with filter paper, Respectively. This process was repeated three times and then dried under reduced pressure and stored at -20 ° C.
수득된 각각의 추출물과 꿀을 하기 표 1에 나타낸 바와 같은 조성비율로 혼합하였다.Each of the obtained extracts and honey were mixed at the composition ratios shown in Table 1 below.
<실시예 2> 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반의 추출 발효물을 포함하는 조성물의 제조Example 2 Preparation of a Composition Containing Extracted Fermented Product of Sukjunghwang, Hwanggi, Green Tea, Peony, Corn Oil, Paddy Rice, Schizandra chinensis, Angelica, Crown, Cinnamon,
상기 실시예 1에서 수득된 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반의 추출물에 각각 락토바실러스 플란타룸(L. plantarum) 균을 상기 추출물 중량을 기준으로 5 중량%의 양으로 접종하여 12시간 동안 배양하여 추출 발효물을 제조하였다. Lactobacillus plantarum (Lactobacillus plantarum ) obtained in Example 1 was added to the extracts of Sulfuric Acid, Hwanggi, Green tea, Peony, Corn oil, Paddy root, Omija, Angelica gigas, In an amount of 5% by weight, and cultured for 12 hours to prepare an extract fermented product.
상기에서 제조된 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반의 추출 발효물과 꿀을 상기 표 1에 나타낸 조성비율로 혼합하여 추출 발효물을 포함하는 조성물을 제조하였다.The extracted fermented products and honey from the above-prepared Sulfuric acid, Hwanggi, Green tea, Peonies, Corn oil, Phellinus linteus, Omija, Angelica gigas, Lt; / RTI >
<시험예 1> 콜라겐 생합성능 측정≪ Test Example 1 > Measurement of collagen biosynthesis performance
콜라겐 생합성능을 측정함으로써 본 발명에 따른 조성물의 주름 개선효과를 관찰하였다. 인체유래 정상 섬유아세포(human normal fibroblast)를 DMEM 배지가 들어 있는 24-웰 마이크로 플레이트에 접종시키고(2 x 105 세포/웰), 5% 농도의 CO2 배양기에 37℃로 24시간 동안 배양하였다. 24시간 후, 각 웰에서 배지를 제거하고 상기 실시예 1 및 2에서 제조된 시료를 처리한 다음 24시간 동안 다시 배양하였다. 24시간 후, 세포배지를 수집하여 샘플을 제조하였다.The effect of improving the wrinkles of the composition according to the present invention was observed by measuring the collagen biosynthesis performance. Human normal fibroblast was inoculated (2 x 10 5 cells / well) into a 24-well microplate containing DMEM medium and cultured in a 5% CO 2 incubator at 37 ° C for 24 hours . After 24 hours, the medium was removed from each well and the samples prepared in Examples 1 and 2 were treated and then re-cultured for 24 hours. After 24 hours, the cell culture medium was collected to prepare a sample.
콜라겐 합성량은 콜라겐 측정 키트(Procollagen Type I C-peptide EIA kit MK101, 다카라, 일본)를 이용하여 (주)다카라의 키트 설명서에 따라 프로콜라겐(procollagen) 타입 I C-펩타이드(Type I C-peptide: PICP)의 양을 측정하였다. 그 결과는 도 1에 나타내었다. The amount of collagen synthesis was measured using a procollagen type I C-peptide (Type I C-peptide, manufactured by Takara Bio Inc.) using a collagen measurement kit (Procollagen Type I C-peptide EIA kit MK101, Takara, Japan) : PICP) was measured. The results are shown in Fig.
도 1은 본 발명에 따른 조성물의 콜라겐 생합성능을 측정하여 나타낸 그래프이다. 여기에서 보듯이, 본 발명에 따른 조성물은 인체유래 섬유아세포에서 콜라겐 생성을 증가시키는 것을 확인할 수 있었으며, 특히 추출물보다 추출 발효물이 효과가 우수함을 알 수 있었다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a graph showing the collagen biosynthesis performance of the composition according to the present invention. As can be seen from the results, it was confirmed that the composition according to the present invention increased collagen production in human fibroblasts. Especially, the extract fermented was more effective than the extract.
<시험예 2> 콜라겐 분해효소 억제효과 측정≪ Test Example 2 > Measurement of collagenase inhibitory effect
콜라겐 분해효소 억제효과를 측정하여 본 발명에 따른 조성물의 주름 개선효과를 관찰하였다. 인체유래 정상 섬유아세포(Human normal fibroblast)를 DMEM 배지가 들어 있는 24-웰 마이크로 플레이트에 접종시키고(2 x 105 세포/웰), 5% 농도의 CO2 배양기에 37℃로 24시간 동안 배양하였다. 24시간 후, 각 웰에서 배지를 제거하고 상기 실시예 1 및 2에서 제조된 시료를 전 처리하고 2시간 후 UVA (5J/cm2)을 각 웰에 처리 후 24시간 동안 다시 배양하였다. 24시간 후, 세포배지를 수집하여 샘플을 제조하였다.Collagenase inhibitory effect was measured to observe the effect of improving the wrinkles of the composition according to the present invention. Human normal fibroblast was inoculated (2 x 10 5 cells / well) into a 24-well microplate containing DMEM medium and cultured in a 5% CO 2 incubator at 37 ° C for 24 hours . After 24 hours, the medium was removed from each well, the samples prepared in Examples 1 and 2 were pretreated, and after 2 hours, UVA (5 J / cm 2 ) was treated in each well and re-cultured for 24 hours. After 24 hours, the cell culture medium was collected to prepare a sample.
콜라겐 분해효소 억제효과 측정은 콜라겐 분해효소 측정 키트 (MMP-1 ELISA kit (QIA55), Merck, Germany)를 이용하여 키트 설명서에 따라 콜라겐 분해효소의 양을 측정하였다. 그 결과를 도 2에 나타내었다. The collagenase inhibitory effect was measured by using a collagenase assay kit (MMP-1 ELISA kit (QIA55), Merck, Germany) according to the kit instructions. The results are shown in Fig.
도 2는 본 발명에 따른 조성물의 콜라겐 분해효소 억제효과를 측정하여 나타낸 그래프이다. 여기에서 보듯이, 본 발명에 따른 조성물은 인체유래 섬유 아세포에서 콜라겐 분해효소의 생성량을 감소시키는 것을 확인할 수 있었으며, 특히 추출물보다 추출 발효물이 효과가 우수함을 알 수 있었다.FIG. 2 is a graph showing measured collagenase inhibitory effects of the composition of the present invention. FIG. As can be seen from the results, it was confirmed that the composition according to the present invention reduced the amount of collagenase produced from the human fibroblasts, and that the extract fermented was more effective than the extract.
<시험예 3> 화장료의 주름개선 효과 측정≪ Test Example 3 > Measurement of wrinkle improvement effect of cosmetics
(단계 1) 영양크림의 제조(Step 1) Preparation of nutritional cream
상기 실시예 1 및 2에서 제조된 한약재 추출물 또는 이의 발효 추출물을 포함하는 영양 크림의 조성은 하기 표 2에 나타낸 바와 같다. 수상인 정제수, 트리에탄올 아민 및 프로필렌글리콜을 70℃로 가열하고 용해시키고, 여기에 유상인 지방산, 유성성분, 유화제 및 방부제를 70℃로 가열하여 용해한 액을 첨가하여 유화시켰다. 유화가 완료된 후 상기 용액을 45℃로 냉각시키고 추출 발효물 및 향을 첨가하고 분산시킨 다음 30℃로 냉각하였다.The compositions of the herbal cream extracts or the nutritional cream containing the fermented extracts prepared in Examples 1 and 2 are shown in Table 2 below. The aqueous phase, purified water, triethanolamine and propylene glycol were heated and dissolved at 70 DEG C, and a fatty acid, an oily component, an emulsifier and an antiseptic agent were heated to 70 DEG C to dissolve the emulsified liquid. After the emulsification is complete, the solution is cooled to 45 DEG C, and the fermented extract and fragrance are added and dispersed and then cooled to 30 DEG C. [
(단계 2) 화장료의 주름 개선효과 관찰(Step 2) Observation of wrinkle improvement effect of cosmetics
한약재 추출물 또는 이의 발효 추출물을 포함하는 화장료의 주름 개선효과를 임상 시험을 통하여 측정하였다. 상기 단계 1에서 제조된 추출물 또는 추출 발효물을 각각 1%를 함유한 영양 크림(제조예 1 및 제조예 2) 및 비교예로서 정제수를 함유한 영양 크림을 사용하였다.The effect of improving the wrinkles of cosmetic preparations containing medicinal herb extracts or fermented extracts thereof was measured by clinical tests. Nutritive creams (Preparation Example 1 and Preparation Example 2) each containing 1% of the extract or fermented extract prepared in
주름개선 효과는 피부탄력 변화의 측정을 통해 평가하였다. 피부탄력의 측정은 온도 24 내지 26℃, 습도 38 내지 40%로 일정하게 유지되는 조건에서 건강한 여성 30명(25 내지 35세)을 대상으로 제조예 1 및 제조예 2의 영양 크림의 3종류와 비교예의 영양 크림을 각각 피검자의 얼굴에 1일 2회씩 3개월 동안 사용하게 한 후, Cutometer SEM 474(Courage + Khazaka, Cologne, 독일)를 이용하여 측정함으로써 수행하였으며, 판정기준은 피부탄력이 없는 경우를 0, 많은 경우를 5로 하여 상대적인 값을 비교하였다. 시험결과는 하기 표 3에 나타내었다.The effect of improving wrinkles was evaluated by measuring changes in skin elasticity. Skin elasticity was measured in 30 healthy women (25 to 35 years old) under the condition that the temperature was kept constant at 24 to 26 DEG C and the humidity was 38 to 40%, and three types of nutritional creams of Production Example 1 and Production Example 2 The nutritional cream of the comparative example was applied to the subject's face twice a day for 3 months, then measured using a cutometer SEM 474 (Courage + Khazaka, Cologne, Germany) And the relative values were compared. The test results are shown in Table 3 below.
상기 표 3에서 보듯이, 본 발명의 제조예 1 및 2의 화장료가 비교 제조예의 화장료에 비해 주름개선 효과가 훨씬 우수하였으며, 특히 추출 발효물 함유 화장료가 매우 우수한 피부탄력도를 가짐을 확인할 수 있었다.As shown in Table 3, the cosmetic compositions of Production Examples 1 and 2 of the present invention were much more effective in improving the wrinkles than the cosmetic compositions of the comparative preparation examples. In particular, it was confirmed that the cosmetic composition containing the extract fermented product had very good skin elasticity.
<시험예 4> 식품의 주름개선 효과 측정≪ Test Example 4 > Measurement of wrinkle improvement effect of food
(단계 1) 음료의 제조(Step 1) Production of beverage
상기 실시예 1 및 2에서 제조된 한약재 추출물 또는 이의 발효 추출물을 포함하는 음료를 하기 표 4에 나타낸 바와 같은 조성으로 제조하였다.The beverage containing the medicinal herb extracts or fermented extracts prepared in Examples 1 and 2 was prepared as shown in Table 4 below.
(단계 2) 음료의 주름 개선효과 관찰(Step 2) Observation of improvement of wrinkle of beverage
한약재 추출물 또는 이의 발효 추출물을 포함하는 음료의 주름 개선효과를 임상 시험을 통하여 측정하였다. 상기 단계 1에서 제조된 추출물을 함유한 음료를 연령 62세, 61세 및 55세의 성인 여성 3인에게 4주간 매일 1회 섭취하게 후 피부 주름 개선효과를 측정하였다.The effect of improving the wrinkles of beverages containing medicinal herb extracts or fermented extracts thereof was measured through clinical studies. The drink containing the extract prepared in
도 3은 내지 도 5는 본 발명에 따른 한약재 추출물을 포함하는 음료의 주름 개선효과를 나타낸 임상 사진이다. 여기에서 보듯이, 본 발명에 따른 한약재 추출물을 포함하는 음료를 섭취한 4주 후 피부 주름이 현격하게 개선되었음을 확인할 수 있다. FIG. 3 through FIG. 5 are clinical photographs showing the effect of improving the wrinkles of beverages containing the medicinal herb extract according to the present invention. As can be seen, it was confirmed that the skin wrinkles were remarkably improved after 4 weeks of ingesting the beverage containing the medicinal herb extract according to the present invention.
<시험예 5> 인체 피부에 대한 안전성 확인 <Test Example 5> Confirmation of safety for human skin
한약재 추출물 또는 추출 발효물이 인체피부에 안전한지 확인하기 위하여, 피부 안전성 검증 실험을 수행하였다. 이를 위해 피부누적 자극시험을 실시하였다. 스쿠알렌을 베이스로 하고 한약재 추출물 또는 추출 발효물을 각각 1% 첨가한 제형을 제조하고, 이를 사용하여 건강한 30명의 성인을 대상으로 윗팔뚝 부위에 격일로 총 9회의 24시간 누적 첩포를 시행하여 한약재 추출물 또는 추출 발효물이 피부에 자극을 주는지 여부를 측정하였다. 첩포 방법은 핀 챔버(Finn chamber, Epitest Ltd, 핀란드)를 이용하였다. 챔버에 상기 각 피부 외용제를 15 ㎕씩 적하한 후 첩포를 실시하였다. 매회 피부에 나타난 반응의 정도를 하기 수학식 1을 이용하여 점수화하였으며, 그 결과를 하기 표 5에 나타내었다.In order to confirm the safety of human skin extract or extract fermented product to human skin, skin safety verification experiment was conducted. For this purpose, cumulative skin irritation test was performed. Based on squalene, a formulation containing 1% of each herbal medicine extract or fermented extract was prepared, and then a total of 9 times 24 hour cumulative pellets were applied to 30 healthy adults on the upper forearm every day, Or whether the extracted fermented product stimulates the skin. A pin chamber (Finn chamber, Epitest Ltd, Finland) was used as the deposition method. 15 [mu] l of each of the above external preparations for skin was dropped into the chamber, followed by applying a patch. The degree of the skin reaction on each occasion was scored using the following
반응도에서 ±는 1점, +는 2점 및 ++는 4점의 점수를 부여하며, 평균반응도가 3 미만일 때 안전한 조성물로 판정된다.A score of ±, a +, and a ++ is given as 1, 2, and 4, respectively, and a safe composition is determined when the average degree of reaction is less than 3.
반응도Average
(스쿠알렌)Control group
(Squalene)
[시험군 1]extract
[Test group 1]
[시험군 2]Extracted fermented product
[Test group 2]
상기 표 5에서 시험군 1 및 2 모두 ±, + 및 ++에 해당하는 사람의 수가 각각 0명, 0명 및 1명이고, 평균 반응도는 각각 0.00, 0.00이었다. 그러므로 평균반응도가 3 이하의 반응도를 나타내므로, 본 발명에 따른 추출물 및 추출 발효물은 뚜렷한 누적자극 양상을 나타내지 않는 인체 피부에 안전한 물질로 판정되었다.In Table 5, the numbers of persons corresponding to ±, + and ++ in
하기에는 본 발명의 조성물을 위한 제제예를 예시한다.Examples of formulations for the composition of the present invention are illustrated below.
<제제예 1> 화장료 제제Formulation Example 1 Cosmetic preparation
1-1. 유연화장수의 제조1-1. Manufacture of softening longevity
하기 표 6에 나타낸 바와 같은 조성으로 한약재 추출물 또는 추출 발효물을 유효성분으로 포함하는 유연 화장수를 통상의 방법에 따라 제조하였다.A lotion lotion containing the herb extract or the fermented extract as an active ingredient in the composition shown in the following Table 6 was prepared according to a conventional method.
1-2. 영양로션의 제조1-2. Manufacture of nutrition lotions
하기 표 7에 나타낸 바와 같은 조성으로 한약재 추출물 또는 추출 발효물을 유효성분으로 포함하는 영양로션을 통상의 방법에 따라 제조하였다. Nutritional lotions containing the herbal medicine extract or the fermented extract as an active ingredient in the composition as shown in the following Table 7 were prepared according to a conventional method.
1-3. 영양크림의 제조1-3. Manufacture of nutrition cream
하기의 표 8과 같이 한약재 추출물 또는 추출 발효물을 유효성분으로 포함하는 영양크림을 통상의 방법에 따라 제조하였다. As shown in Table 8 below, a nutritional cream containing the herb extract or the fermented extract as an active ingredient was prepared according to a conventional method.
1-4. 마사지 크림의 제조1-4. Manufacture of massage cream
하기 표 9에 나타낸 바와 같은 조성으로 한약재 추출물 또는 추출 발효물을 유효성분으로 포함하는 마사지 크림을 통상의 방법에 따라 제조하였다. Massage cream containing the herb extract or the fermented extract as an active ingredient in the composition shown in the following Table 9 was prepared according to a conventional method.
1-5. 팩의 제조1-5. Manufacture of packs
하기 표 10에 나타낸 바와 같은 조성으로 한약재 추출물 또는 추출 발효물을 유효성분으로 포함하는 팩을 통상의 방법에 따라 제조하였다. A pack containing the herb extract or the fermented extract as an active ingredient in the composition shown in the following Table 10 was prepared according to a conventional method.
제제예 2 : 약학적 제제의 제조Formulation Example 2: Preparation of pharmaceutical preparations
2-1. 산제의 제조 2-1. Manufacture of Powder
한약재 추출물 또는 추출 발효물을 유효성분으로 포함하는 산제를 제조하기 위하여, 하기 표 11의 성분을 혼합한 다음 기밀포에 충진하여 산제를 제조하였다.In order to prepare powders containing the herbal medicine extract or the fermented extract as an active ingredient, the ingredients shown in Table 11 below were mixed and filled in airtight bags to prepare powders.
상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조하였다.The above components were mixed and packed in airtight bags to prepare powders.
2-2. 정제의 제조2-2. Manufacture of tablets
한약재 추출물 또는 추출 발효물을 유효성분으로 포함하는 정제를 제조하기 위하여, 하기 표 12의 성분을 혼합한 다음 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다. In order to prepare tablets containing the medicinal herb extract or the fermented extract as an active ingredient, tablets were prepared by mixing the ingredients listed in Table 12 below and tableting according to a conventional preparation method of tablets.
2-3. 캡슐제의 제조2-3. Preparation of capsules
한약재 추출물 또는 추출 발효물을 유효성분으로 포함하는 캡슐제를 제조하기 위하여, 하기 표 13의 성분을 혼합한 다음 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다. In order to prepare a capsules containing the herbal medicine extract or the fermented extract as an active ingredient, the following ingredients of Table 13 were mixed and filled in gelatin capsules according to the conventional preparation method of capsules to prepare capsules.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (15)
숙지황 2 내지 10 중량%, 황기 2 내지 10 중량%, 녹차 2 내지 10 중량%, 작약 2 내지 10 중량%, 산수유 1 내지 8 중량%, 갈근 1 내지 8 중량%, 오미자 1 내지 8 중량%, 당귀 0.5 내지 5 중량%, 천궁 0.5 내지 5 중량%, 계피 0.5 내지 5 중량%, 대회향 0.1 내지 2 중량%, 돈태반 1 내지 3 중량% 및 꿀 40 내지 60 중량%을 포함하는 피부 주름 예방 또는 개선을 위한 화장료 조성물.The method according to claim 1,
2 to 10% by weight of steamed rice, 2 to 10% by weight of green tea, 2 to 10% by weight of green tea, 2 to 10% by weight of peanut, 1 to 8% by weight of corn oil, 1 to 8% by weight of Puerariae, 1 to 8% The prevention or improvement of skin wrinkles comprising 0.5 to 5% by weight of celery, 0.5 to 5% by weight of cinnamon, 0.5 to 5% by weight of cinnamon, 0.1 to 2% by weight of carrot, 1 to 3% by weight of placenta and 40 to 60% ≪ / RTI >
상기 추출물은 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반 각각의 중량의 10배 양(w/v)의 증류수를 넣어 90℃에서 4시간 추출한 후 여과지로 상층액을 회수하는 공정을 3회 반복하여 모은 후 감압건조시켜 제조된 것임을 특징으로 하는 피부 주름 예방 또는 개선을 위한 화장료 조성물.The method according to claim 1,
The extract was extracted with distilled water in an amount of 10 times (w / v) of the weight of each of Sukjunggwang, Hwanggi, Green tea, Peony, Sansui, Pueraria, Omija, Angelica gigas, And recovering the supernatant with filter paper is repeated three times to collect and then dried under reduced pressure to prevent or improve the wrinkle of the skin cosmetic composition.
상기 추출 발효물은 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반의 각 추출물에 유산균을 상기 각 추출물 중량을 기준으로 4 내지 6 중량%의 양으로 접종하여 10 내지 20시간 동안 배양하여 발효된 것임을 특징으로 하는 피부 주름 예방 또는 개선을 위한 화장료 조성물.The method according to claim 1,
The extracted fermented product is prepared by adding lactic acid bacterium to each extract of Sukjiwha, Hwanggi, Green tea, Peony root, Corn oil, Phellinus linteus, Omija, Angelica keiskei, Wherein the composition is fermented by being inoculated and cultured for 10 to 20 hours.
상기 유산균이 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 플란타룸(L. plantarum), 락토바실러스 애시도필러스(L. acidophilus), 락토바실러스 불가리쿠스(L.bulgaricus), 비피도박테리움 롱굼(Bifidobacterium longum), 비피도박테리움 비피둠(B. bifidum) 또는 이들의 혼합균인 것을 특징으로 하는 피부 주름 예방 또는 개선을 위한 화장료 조성물.5. The method of claim 4,
When the lactic acid bacterium is Lactobacillus casei casei, L. plantarum , L. acidophilus , L. bulgaricus , Bifidobacterium longum , Bifidobacterium, Bifidobacterium longum , Bifidobacterium longum , B. bifidum or a mixture thereof. The cosmetic composition for preventing or improving wrinkles of the skin.
숙지황 2 내지 10 중량%, 황기 2 내지 10 중량%, 녹차 2 내지 10 중량%, 작약 2 내지 10 중량%, 산수유 1 내지 8 중량%, 갈근 1 내지 8 중량%, 오미자 1 내지 8 중량%, 당귀 0.5 내지 5 중량%, 천궁 0.5 내지 5 중량%, 계피 0.5 내지 5 중량%, 대회향 0.1 내지 2 중량%, 돈태반 1 내지 3 중량% 및 꿀 40 내지 60 중량%을 포함하는 피부 주름 예방 또는 개선을 위한 약학적 조성물.The method according to claim 6,
2 to 10% by weight of steamed rice, 2 to 10% by weight of green tea, 2 to 10% by weight of green tea, 2 to 10% by weight of peanut, 1 to 8% by weight of corn oil, 1 to 8% by weight of Puerariae, 1 to 8% The prevention or improvement of skin wrinkles comprising 0.5 to 5% by weight of celery, 0.5 to 5% by weight of cinnamon, 0.5 to 5% by weight of cinnamon, 0.1 to 2% by weight of carrot, 1 to 3% by weight of placenta and 40 to 60% ≪ / RTI >
상기 추출물은 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반 각각의 중량의 10배 양(w/v)의 증류수를 넣어 90℃에서 4시간 추출한 후 여과지로 상층액을 회수하는 공정을 3회 반복하여 모은 후 감압건조시켜 제조된 것임을 특징으로 하는 피부 주름 예방 또는 개선을 위한 약학적 조성물.The method according to claim 6,
The extract was extracted with distilled water in an amount of 10 times (w / v) of the weight of each of Sukjunggwang, Hwanggi, Green tea, Peony, Sansui, Pueraria, Omija, Angelica gigas, And recovering the supernatant with filter paper is repeated three times to collect and then dried under reduced pressure to prevent or improve the wrinkle of the skin.
상기 추출 발효물은 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반의 각 추출물에 유산균을 상기 각 추출물 중량을 기준으로 4 내지 6 중량%의 양으로 접종하여 10 내지 20시간 동안 배양하여 발효된 것임을 특징으로 하는 피부 주름 예방 또는 개선을 위한 약학적 조성물.The method according to claim 6,
The extracted fermented product is prepared by adding lactic acid bacterium to each extract of Sukjiwha, Hwanggi, Green tea, Peony root, Corn oil, Phellinus linteus, Omija, Angelica keiskei, Wherein the composition is fermented by being inoculated and cultured for 10 to 20 hours.
상기 유산균이 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 플란타룸(L. plantarum), 락토바실러스 애시도필러스(L. acidophilus), 락토바실러스 불가리쿠스(L.bulgaricus), 비피도박테리움 롱굼(Bifidobacterium longum), 비피도박테리움 비피둠(B. bifidum) 또는 이들의 혼합균인 것을 특징으로 하는 피부 주름 예방 또는 개선을 위한 약학적 조성물.10. The method of claim 9,
When the lactic acid bacterium is Lactobacillus casei casei, L. plantarum , L. acidophilus , L. bulgaricus , Bifidobacterium longum , Bifidobacterium, Bifidobacterium longum , Bifidobacterium longum , B. bifidum or a mixed microorganism thereof.
숙지황 2 내지 10 중량%, 황기 2 내지 10 중량%, 녹차 2 내지 10 중량%, 작약 2 내지 10 중량%, 산수유 1 내지 8 중량%, 갈근 1 내지 8 중량%, 오미자 1 내지 8 중량%, 당귀 0.5 내지 5 중량%, 천궁 0.5 내지 5 중량%, 계피 0.5 내지 5 중량%, 대회향 0.1 내지 2 중량%, 돈태반 1 내지 3 중량% 및 꿀 40 내지 60 중량%을 포함하는 피부 주름 예방 또는 개선을 위한 식품 조성물.12. The method of claim 11,
2 to 10% by weight of steamed rice, 2 to 10% by weight of green tea, 2 to 10% by weight of green tea, 2 to 10% by weight of peanut, 1 to 8% by weight of corn oil, 1 to 8% by weight of Puerariae, 1 to 8% The prevention or improvement of skin wrinkles comprising 0.5 to 5% by weight of celery, 0.5 to 5% by weight of cinnamon, 0.5 to 5% by weight of cinnamon, 0.1 to 2% by weight of carrot, 1 to 3% by weight of placenta and 40 to 60% ≪ / RTI >
상기 추출물은 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반 각각의 중량의 10배 양(w/v)의 증류수를 넣어 90℃에서 4시간 추출한 후 여과지로 상층액을 회수하는 공정을 3회 반복하여 모은 후 감압건조시켜 제조된 것임을 특징으로 하는 피부 주름 예방 또는 개선을 위한 식품 조성물.12. The method of claim 11,
The extract was extracted with distilled water in an amount of 10 times (w / v) of the weight of each of Sukjunggwang, Hwanggi, Green tea, Peony, Sansui, Pueraria, Omija, Angelica gigas, And recovering the supernatant with filter paper is repeated three times, followed by drying under reduced pressure to prepare a food composition for preventing or improving skin wrinkles.
상기 추출 발효물은 숙지황, 황기, 녹차, 작약, 산수유, 갈근, 오미자, 당귀, 천궁, 계피, 대회향 및 돈태반의 각 추출물에 유산균을 상기 각 추출물 중량을 기준으로 4 내지 6 중량%의 양으로 접종하여 10 내지 20시간 동안 배양하여 발효된 것임을 특징으로 하는 피부 주름 예방 또는 개선을 위한 식품 조성물.12. The method of claim 11,
The extracted fermented product is prepared by adding lactic acid bacterium to each extract of Sukjiwha, Hwanggi, Green tea, Peony root, Corn oil, Phellinus linteus, Omija, Angelica keiskei, Wherein the composition is fermented by being inoculated and cultured for 10 to 20 hours.
상기 유산균이 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 플란타룸(L. plantarum), 락토바실러스 애시도필러스(L. acidophilus), 락토바실러스 불가리쿠스(L.bulgaricus), 비피도박테리움 롱굼(Bifidobacterium longum), 비피도박테리움 비피둠(B. bifidum) 또는 이들의 혼합균인 것을 특징으로 하는 피부 주름 예방 또는 개선을 위한 식품 조성물.15. The method of claim 14,
When the lactic acid bacterium is Lactobacillus casei casei, L. plantarum , L. acidophilus , L. bulgaricus , Bifidobacterium longum , Bifidobacterium, Bifidobacterium longum , Bifidobacterium longum , B. bifidum , or a mixture thereof. ≪ RTI ID = 0.0 > 18. < / RTI >
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170105907A KR20190020946A (en) | 2017-08-22 | 2017-08-22 | A composition for preventing or improving skin wrinkle comprising herb extracts or fermentation products thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170105907A KR20190020946A (en) | 2017-08-22 | 2017-08-22 | A composition for preventing or improving skin wrinkle comprising herb extracts or fermentation products thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190089385A Division KR102041927B1 (en) | 2019-07-24 | 2019-07-24 | A composition for preventing or improving skin wrinkle comprising herb extracts fermentation products thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20190020946A true KR20190020946A (en) | 2019-03-05 |
Family
ID=65760536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170105907A KR20190020946A (en) | 2017-08-22 | 2017-08-22 | A composition for preventing or improving skin wrinkle comprising herb extracts or fermentation products thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20190020946A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113925805A (en) * | 2021-09-14 | 2022-01-14 | 上海植纳生物科技有限公司 | Peony cell fermentation liquor and preparation method and application thereof |
KR20220120948A (en) * | 2021-02-24 | 2022-08-31 | 이경미 | Cosmetic composition for improving melasma, freckles, whitenings and wrinkle comprising extract of fermented chestnut inner shell, angelica dahurica, portulace oleracea, armeniacae and mori dadicis cortex and preparation method thereof |
-
2017
- 2017-08-22 KR KR1020170105907A patent/KR20190020946A/en active Search and Examination
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220120948A (en) * | 2021-02-24 | 2022-08-31 | 이경미 | Cosmetic composition for improving melasma, freckles, whitenings and wrinkle comprising extract of fermented chestnut inner shell, angelica dahurica, portulace oleracea, armeniacae and mori dadicis cortex and preparation method thereof |
CN113925805A (en) * | 2021-09-14 | 2022-01-14 | 上海植纳生物科技有限公司 | Peony cell fermentation liquor and preparation method and application thereof |
CN113925805B (en) * | 2021-09-14 | 2023-05-23 | 上海植纳生物科技有限公司 | Peony cell fermentation broth and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102041927B1 (en) | A composition for preventing or improving skin wrinkle comprising herb extracts fermentation products thereof | |
KR101059471B1 (en) | Cosmetic composition for skin aging | |
KR102113193B1 (en) | Composition for improving skin conditions comprising artemisiae annuae herba, centella asiatica and green tea extract or fraction thereof and method for improving skin conditions using the same | |
KR102142930B1 (en) | A composition for promoting melanin synthesis comprising flower extract of milk thistle | |
KR102111752B1 (en) | Composition for promoting collagen synthesis | |
KR101914345B1 (en) | A moisturizing and anti-wrinkle cosmetic composition comprising fermented soybean, fermented rice, fermented potato, fermented ginseng and fermented adlay extract and preparation method of thereof | |
KR102009676B1 (en) | Cosmetic Composition Comprising Bamboo Fermented Extract | |
KR102004366B1 (en) | A cosmetic composition comprising centipeda minima extract | |
CN112137919B (en) | Application of dictyophora indusiata egg extract in preparation of external beauty and skin care products and external beauty and skin care products based on same | |
KR20190020946A (en) | A composition for preventing or improving skin wrinkle comprising herb extracts or fermentation products thereof | |
KR101988830B1 (en) | Composition for moisturizing, improving skin elasticity, and female breast expansion | |
KR101189794B1 (en) | Composition for external application to the skin containing Hibiscus cannabinus extract | |
KR102176883B1 (en) | Composition for skin regeneration, anti-wrinkle, or wound healing containing Prunus persica resin | |
KR102224313B1 (en) | Composition for skin whitening comprising scutellaria alpina extract | |
KR20130136753A (en) | Cosmetic composition comprising cercis chinensis or reynoutria japonica for. elata extract for skin whitening | |
KR102178096B1 (en) | Composition for skin-whitening comprising Amaranth extracts | |
KR20100092922A (en) | A skin whintening cosmetic composition containing a oriental herb extracts mixture stabilized by nanoliposome | |
KR20170136919A (en) | Composition for improving skin condition comprising herb extracts mixture | |
CN113631227A (en) | Antiaging agent, antioxidant, antiinflammatory agent, whitening agent, and cosmetic | |
KR102525129B1 (en) | Composition comprising fermented extracts of unripe plum and manufacturing method thereof | |
KR102561258B1 (en) | Composition for controlling sebum and improving pore comprising Jasminum Officinale, Salix Alba (willow) bark and Solanum melogena fruit extract | |
KR102262791B1 (en) | A composition for improving skin function comprising fermented herb extracts | |
KR102628844B1 (en) | Cosmetic composition for anti-oxidation, skin whitening and anti-wrinkle containing a mixed fermentation extracts of Wisteria floribunda flowers, Aralia elata flowers, Camellia japonica leafs and Camellia japonica flowers as effective component | |
KR102154140B1 (en) | Composition comprising tulip leaf extract, amorphophallus paeoniifolius hydrolysis extract and parrot ferment extract | |
KR102012170B1 (en) | Composition comprising extracts of banana, cherry, and walnut for anti-skin aging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
AMND | Amendment |